Elevated TIDE score usually indicates stronger immune evasion mechanisms in the tumor and poorer immunotherapy efficacy (72), which is associated with reduced response rate to immunotherapies such as PD-1/PD-L1 inhibitors and CTLA-4 inhibitors. This evidence concerns the gene CD274 and neoplasm.